Psoriasis Clinical Trial

Topical SGX302 for Mild-to-Moderate Psoriasis

Summary

To evaluate SGX302 (topical hypericin ointment) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6-months duration that involves the body (trunk and/or limbs) that is amenable to topical treatment and opaque coverage after application.
Have a static Investigator Global Assessment (IGA)/Psoriasis Area and Severity Index (PASI) of disease severity of mild or moderate on the body (trunk and/or limbs).
Have lesions involving 2-30% of the body (trunk and/or limbs). For subjects with scalp psoriasis included in the treatment area, the total treatment area on body and scalp must not exceed 30%.

Exclusion Criteria:

Use of topical anti psoriatic therapy within one week prior to the beginning of the study and willing to not use other psoriasis treatments for 4 weeks following completion of the treatment portion of the study.
Received systemic biologic therapy to treat psoriasis within 12 weeks prior to the beginning of the study.
Received systemic psoriasis therapy within 4 weeks prior to the beginning of the study.
Received phototherapy (including laser) or photodynamic (light activated drug) therapy within 4 weeks prior to the beginning of the study.

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

42

Study ID:

NCT05442190

Recruitment Status:

Recruiting

Sponsor:

Soligenix

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Therapeutics Clinical Research
San Diego California, 92123, United States More Info
Noe Guerrero
Contact
858-571-6800
Neal Bhatia, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

42

Study ID:

NCT05442190

Recruitment Status:

Recruiting

Sponsor:


Soligenix

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.